Dissemin is shutting down on January 1st, 2025

Published in

Society of Nuclear Medicine, Journal of Nuclear Medicine, 8(54), p. 1339-1346, 2013

DOI: 10.2967/jnumed.112.116293

Links

Tools

Export citation

Search in Google Scholar

18F-EF5 PET Imaging as an Early Response Biomarker for the Hypoxia-Activated Prodrug SN30000 Combined with Radiation Treatment in a Non–Small Cell Lung Cancer Xenograft Model

Journal article published in 2013 by Satish K. Chitneni, Gerald T. Bida, Hong Yuan, Gregory M. Palmer, Michael P. Hay ORCID, Thorsten Melcher, William R. Wilson, Michael R. Zalutsky, Mark W. Dewhirst
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
  • If required by funding agency
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Hypoxia is a significant therapeutic problem for solid tumors because hypoxic cells are treatment-resistant and more aggressive. Hypoxia-activated prodrugs such as SN30000 use a mechanism of activation in hypoxic cells similar to that of 2-nitroimidazole hypoxia PET tracers. Therefore, we have evaluated the usefulness of 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-18F-pentafluoropropyl)-acetamide (18F-EF5) PET to monitor and predict tumor response to SN30000 plus radiation treatment (RT).